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Summary
Background Children and adolescents have poorer HIV treatment outcomes than adults. We aimed to assess the 
effect of community-based support for caregivers of HIV-infected children and adolescents, who are key mediators to 
children engaging with care, on treatment outcomes.
Methods In this open-label, randomised contolled trial, we recruited children aged 6–15 years with newly-diagnosed 
HIV attending primary health-care clinics in Harare, Zimbabwe. Children were randomly assigned to receive 
decentralised primary health-care clinic-based HIV care (control group), according to national guidelines for 
18 months, or decentralised care plus structured support visits by trained community health workers (intervention 
group) according to national guidelines for 18 months. Primary outcomes were the proportion of participants who 
died or had an HIV viral load of 400 copies per mL or higher at 12 months after antiretroviral therapy (ART) initiation 
(among those who started ART within 6 months of enrolment); and the proportion who missed two or more scheduled 
clinic visits by 18 months post-enrolment (among all participants). Analyses were complete-case, modified-intention-
to-treat. This trial is registered with the Pan African Clinical Trials Registry, number PACTR201212000442288.
Findings Between January, 2013, and January, 2015, 470 participants tested HIV-positive at seven study primary health-
care clinics and were screened for eligibility. Of the 334 eligible children and adolescents, 166 were randomly assigned 
to the intervention group and 168 to the control group. The median age of participants was 11 years (IQR 8–13) and 
178 (53%) were girls. Among the 238 participants who started ART within 6 months of enrolment, the proportion 
who died or had a viral load of 400 copies/mL or higher at 12 months post-ART initiation was significantly lower in 
the intervention group than in the control group (31 [33%] of 94 participants vs 42 [49%] of 86 participants, respectively, 
adjusted odds ratio [aOR] 0·46, 95% CI 0·23–0·89; p=0·02). The proportion of children missing two or more 
scheduled visits was similar in the intervention group and control group (27 [17%] of 155 vs 30 [18%] of 165, aOR 0·92, 
95% CI 0·49–1·74; p=0·79). One participant withdrew from the trial 240 days after enrolment and 12 died during 
follow-up (five in the intervention group; seven in the control group).
Interpretation Community-based support for caregivers has high potential for scalability and could have a 
substantial effect on HIV virological suppression in children and adolescents, a group with disproportionately poor 
treatment outcomes.
Funding Wellcome Trust.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
The scale-up of interventions to prevent mother-to-child 
HIV transmission has led to a halving in HIV infections 
in children since 2000.1 However, the number of HIV-
related deaths among the generation of children who are 
surviving to adolescence is rising despite the expansion 
of antiretroviral therapy (ART) coverage worldwide.2 This 
trend is being driven mainly by mortality in sub-Saharan 
Africa, where 90% of the world’s HIV-infected children 
live.3 Multiple factors drive this mortality, but most paths 
eventually lead to poor ART adherence and problems 
with retention in HIV care. Findings of studies in both 
high-income and low-income settings have shown poorer 
outcomes in children and adolescents compared with 
adults across the HIV care cascade, with the proportion 
virally suppressed as low as 63% at 12 months after ART 
initiation in those younger than 18 years, and consequent 
high risk of treatment failure and mortality.3,4 However, 
few interventions have focused on improving HIV-
related outcomes in this age group.5,6
The pressure on health systems in high HIV prevalence 
resource-limited settings has led to the decentralisation 
of HIV services from secondary to primary care and 
task-shifting to nurses and non-clinical staff.7 These 
Articles
176 www.thelancet.com/child-adolescent   Vol 1   November 2017
strategies, although having shown equivalent outcomes, 
are reaching their limits as increasing numbers of 
patients initiate ART, overwhelming workforce capacity.8,9 
Community based interventions to support HIV care 
outside clinics are being increasingly promoted to relieve 
pressure on health facilities and provide more patient-
centred services. A systematic review of community-based 
interventions to support adherence to treatment and 
retention in care noted similar outcomes to facility-based 
ART delivery.10 However, the interventions were mainly 
implemented among clinically stable adult patients; only 
three of the 22 studies included children. As ART is scaled 
up, community-based approaches could be a mechanism 
for meeting the growing health needs of children and 
adolescents in high HIV prevalence settings.8
Caregivers are key mediators for children accessing and 
maintaining treatment, and their own physical and 
emotional health, understanding of HIV care, and access 
to supportive social networks affects their ability to ensure 
children’s retention in care and adherence to treatment.11,12 
In two studies,13,14 absence of a caregiver at a child’s clinic 
appointments was associated with lower adherence to 
treatment and higher odds of virological failure. Formative 
research suggested that support for caregivers would lead 
to better outcomes in children living with HIV.15 We aimed 
to assess the effect of community-based support provided 
by trained community health workers to caregivers of 
children and adolescents living with HIV, on adherence to 
treatment and retention in HIV care in Harare, Zimbabwe.
Methods
Study design
In this open-label, randomised controlled trial, we 
recruited boys and girls aged 6–15 years with newly-
diagnosed HIV attending seven primary health-care 
clinics in Harare, Zimbabwe. Ethical approval was 
granted by the Medical Research Council of Zimbabwe 
and the ethics committees of the Biomedical Research 
and Training Institute and the London School of Hygiene 
& Tropical Medicine, London, UK. Written informed 
consent from guardians and age-appropriate assent from 
participants were obtained. 
Research in context
Evidence before this study
Maintaining HIV viral suppression is essential to reduce the risk 
of mortality, onward transmission of HIV, and development of 
drug resistance. This requires an individual who is diagnosed 
with HIV to link to care, start antiretroviral therapy (ART), 
remain in care, and have sustained high levels of treatment 
adherence. We searched Medline for systematic reviews of any 
interventions to improve either linkage, adherence, or retention 
in care up to February, 2017, using the search terms *HIV or 
Antiretroviral therapy or ART or ARV) AND (adherence) AND 
(review or meta-analysis). We identified three systematic 
reviews investigating interventions aimed at improving viral 
suppression in HIV-infected individuals receiving ART, and 
two reviews focused on improving treatment outcomes in 
HIV-infected adolescents. A meta-analysis included 47 trials 
reporting virological outcomes, of which three were done in 
youth or children, two included adolescents (although 
age-disaggregated data were not presented), and the remainder 
were done in adults. Of the 16 intervention packages, cognitive 
behaviour therapy (OR 1·46, 95% CI 1·05–2·12) and supporter 
interventions (1·28, 1·01–1·71) were superior to standard of 
care. Only 12 of the trials were done in low and middle-income 
countries (LMICs) and none showed an effect of interventions 
on viral load outcomes. Similarly, systematic reviews 
investigating the effect of peer interventions (17 trials of which 
eight were from LMICs, and one included children and 
adolescents) reported no effect on viral suppression; and 
home-based interventions among HIV infected adults in 
sub-Saharan Africa reported only a small and non-significant 
effect (pooled OR 1·13, 95% CI 0·51–2·52). We found no trials 
assessing the effect of interventions on viral load outcomes in 
adolescents in LMICs; the studies that were reported from 
high-income settings were mainly cohort studies or analysed 
routinely collected programme data with inadequate control 
groups, had small sample sizes, and investigated interventions 
that are not feasible to implement in resource-limited settings.
Added value of the study
Our findings show that community-based support provided by 
community health workers to caregivers substantially reduces 
the risk of virological failure in HIV-infected children and 
adolescents. This is the first randomised trial of an intervention 
to improve treatment outcomes in children and adolescents, 
done in a LMIC, and with the outcome assessed using HIV viral 
load. The need for consent is often a major obstacle to 
including minors in studies and is one reason why few studies 
have been done in this age-group. This study adds to the sparse 
evidence base for interventions in older children and 
adolescents, in whom care outcomes have consistently been 
reported to be worse than in adults, and is also the first trial to 
show the effect of a community-based intervention on 
virological outcomes. The intervention focused on the 
caregivers who are key to children accessing care, and the trial 
showed an impact across the HIV care cascade.
Implications of the available evidence
In recent years, community-based interventions and use of 
community health workers have been widely promoted and 
recommended to relieve pressure on weak health systems and 
provide more patient-centred services. The study was done in a 
routine health-care setting using a cadre of workers that already 
exist in many African health systems, and therefore the 
intervention has high potential for scalability. Further studies that 
replicate this model are needed to understand  contexual factors 
that will influence implementation and cost-effectiveness.
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Participants
The study was done in seven communities in south-
western Harare. Each community is served by a primary 
health-care clinic providing acute and antenatal care 
services. Provider-initiated HIV testing and counselling 
at all health facilities has been standard of care in 
Zimbabwe since 2007. The inclusion criteria were 
age 6–15 years, newly-diagnosed HIV infection, and 
residence in and planning to receive HIV care in one of 
the study communities.
Before the study, children were receiving HIV care 
including initiation of ART at hospital HIV outpatient 
services. This was in contrast to adults, of whom an 
increasing number were being initiated on ART at their 
nearest primary health-care clinic or transferred there for 
continuing care once they were stable on treatment. In a 
cross-sectional study in a public-sector HIV treatment 
clinic based at the largest hospital in Harare, of the children 
who had started ART between 2004 to 2011 aged 5–9 years 
and 10–14 years and had been taking ART for at least 
6 months, the proportion who had a HIV viral load higher 
than 1000 copies/mL was 21% and 40%, respectively.16
From January, 2013, as part of the study, specialist 
nurse-led HIV care services for children were established 
at the seven study primary health-care clinics. Designated 
nurses from each primary health-care clinic and research 
nurses underwent training on delivery of paediatric HIV 
care including initiation of ART, at first-level facilities. 
The training used Ministry of Health and Child Care 
training tools for paediatric HIV care provision and the 
WHO Integrated Management of Childhood Illness 
clinical guidelines, and incorporated additional training 
on adolescent HIV care issues.
HIV treatment followed national guidelines and was 
provided to participants at primary health-care clinics by 
research nurses and routine clinical staff, supported by 
the study physician. This included cotrimoxazole 
prophylaxis for all patients, ART prescription (including 
ART initiation), management of intercurrent illness with 
referral to secondary care if indicated, and disclosure and 
adherence counselling. HIV treatment followed national 
guidelines (threshold of CD4 count <350 cells per µl until 
March, 2014; <500 cells per µl subsequently) and ART 
was provided by the National ART Programme. Those 
starting ART were seen once every 2 weeks for the 
first month, once a month for the next 2 months, and 
once every 3 months thereafter. Those not taking ART 
were followed up every 2 weeks for the first month and 
once every 3 months thereafter.
Randomisation and masking
Children were randomly assigned (1:1) to receive 
decentralised primary health-care clinic-based HIV care 
(control group), monthly or every 3 months (according to 
national guidelines) for 18 months, or decentralised care 
plus structured support visits (either at home or at a 
location of the caregiver’s and participant’s choice) by 
trained community health workers (intervention group) 
according to national guidelines for 18 months. The 
target sample size for each clinic was proportional to the 
estimated number of children living with HIV, aged 
6–15 years, in the clinic catchment area (determined 
through a previous enumeration survey).17
After consent to participate was obtained, a study 
number was allocated sequentially to each participant. 
Randomisation was done via random-number tables 
generated by a computer software programme by a 
statistician who had no role in the rest of the study; the 
data manager had sole access to the password-protected 
randomisation file. To ensure allocation concealment, 
the group allocation for each study number was provided 
through a mobile SMS to the recruiting research nurse. 
In households where more than one child was eligible, 
the first presenting child was enrolled, and subsequent 
children were allocated to the same group and were 
excluded from the trial analysis. Community health 
workers and nurses were not masked to allocation, but 
laboratory staff were. Masking was achieved by use of 
study ID numbers on forms. 
Procedures
At enrolment, the research nurses administered a clinical 
and social history to the caregiver using a structured 
questionnaire, and conducted a standardised examination, 
a brief HIV symptom screen was done, and incident 
clinical events (eg, admittance to hospital, unscheduled 
clinic visits, and infections), and height and weight were 
recorded and a prescription for cotrimoxazole and ART 
(where indicated) was given. The dose of ART was 
checked at every visit and adjusted according to weight. 
Self-reported adherence (reported by the caregiver for 
younger participants) was assessed once every 6 months 
using a visual analogue scale (VAS) and missed pills on 
3-days recall.18 Participants who wished to transfer to 
another facility for care were given a referral and clinical 
history record and were not followed-up further.
HIV-1 viral load testing was done 12 months after ART 
initiation and 18 months after enrolment among those 
who initiated ART using the COBAS Ampliprep/
Taqman 48 v2.0 platform (Roche Molecular Systems, 
Inc., Branchburg, NJ, USA). Participants who missed 
appointments were offered an alternative time, but were 
considered to have missed a visit even if they attended 
the alternative appointment. Participants were followed 
up for 18 months after randomisation, and continued to 
receive care at their primary health-care clinic following 
the end of the trial. Participants who were lost-to-follow-
up were contacted via phone and home visits to ascertain 
their outcome.
The intervention used a strength-based case manage-
ment approach, adapted from the Antiretroviral Treatment 
Access Study interventions.19 This approach focuses on 
skills, resources, and positive experiences in the face of 
adversity, and leads participants through a process of 
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identifying barriers and practical solutions. Formative 
research, including a review of existing support 
programmes, mapping of local services, and qualitative 
interviews with caregivers, children and health-care 
providers, was undertaken to tailor the intervention to the 
local context.15
The intervention involved one-to-one sessions with 
children’s primary caregivers delivered by community 
health workers, done over 18 months after enrolment at 
crucial points in a participant’s progression through 
HIV diagnosis, treatment initiation, and long-term 
care, at a location of the caregiver’s choice. The sessions 
were directed at the primary caregiver, although if the 
caregiver was not present, the community health 
worker could meet with another household member, 
relative or, rarely, the enrolled child, depending on age 
and family circumstances. The community health 
worker visits followed the clinic appointment schedule 
where possible. After two initial visits to establish 
rapport, there were three intensive and structured 
community health worker sessions and then shorter, 
less formal visits unless concerns were identified, in 
which case additional visits were scheduled. Both 
sessions aimed to assess the child’s personal and family 
circumstances, support engagement with care, offer 
treatment literacy, clarify issues raised at clinic 
appointments, refer participants or families to local 
organisations offering additional support services, and 
provide a link to clinics by reminding caregivers of 
scheduled appointments. Clinic staff and community 
health workers met regularly to check participants’ 
attendance and share issues that could be addressed 
within the clinic or community settings. The structure, 
timing, and content of the sessions are detailed in the 
appendix. Children not eligible for ART received the 
same community health worker visits to encourage 
retention in care during the pre-ART phase. Once they 
become eligible to initiate ART, the three intensive 
sessions were repeated to address treatment.
Eligibility criteria for community health workers 
included residence in the local community for at least 
5 years, functional literacy (able to read and fill in 
rudimentary record-keeping forms, basic comprehension 
of literature such as health pamphlets), willingness to 
travel on foot between households and visit the local 
clinic, and experience of nurturing others (including 
caring for their own or others’ children, sick or elderly 
family members, or previous work experience in a caring 
capacity). Community health workers underwent a 
2 week training programme, followed by a further 
2 weeks of intensive on-the-job supervision. The training 
programme had three components namely provision of 
HIV literacy (information related to HIV transmission, 
prevention and treatment), orientation to challenges 
faced by children and families in initiating and 
maintaining treatment, and instruction on intervention 
content and development of specific skills to achieve the 
objective of each visit. Training involved illustration 
through examples and case studies, role plays, and 
participatory activities (training resources available on 
request). During the intensive 2 week supervision 
period, each community health worker was shadowed 
for a day as they did visits followed by a debrief 
discussion. A refresher workshop was held at 2 months 
and then every 6–9 months. In addition, monthly 
meetings with the community health workers were held 
to discuss concerns, share initial experiences and 
problems, and facilitate a team approach to seek 
solutions to challenges confronted in their work. 
community health workers were contracted on a 
probationary period for 2 months and their contract 
confirmed after a refresher workshop held at the end of 
the probationary period. Each community health worker 
was given a monthly stipend of US$20.
Outcomes
The primary outcomes were the proportion of 
participants who had died or were virally unsuppressed 
Figure 1: Trial profile
470 children and adolescents assessed for eligibility
334 randomly assigned
166 allocated to intervention 
group
Viral non-suppression/death
94 data available on viral 
load/death 12 months
post-ART 
28 data missing
136 excluded
51 not living in study communities
2 not aged 6–15 years
36 declined to participate
34 sought care outside study clinics
13 another participant in household 
already enrolled
44 did not initiate ART
within 6 months
of enrolment
43 not ART eligible
1 eligible but missed
all visits
≥2 missed visits
155 data available on missed
visits
6 data missing
5 transferred out before 
2 visits were scheduled
168 allocated to control group
Viral non-suppression/death
86 data available on viral 
load/death 12 months
post-ART 
30 data missing
52 did not initiate ART
within 6 months
of enrolment
51 not ART eligible
1 eligible but missed
all visits
≥2 missed visits
165 data available on missed
visits
3 data missing
See Online for appendix
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(as defined by HIV-1 viral load ≥400 copies per mL) 
12 months after starting ART, among those who initiated 
ART within 6 months of randomisation, and the 
proportion of all participants who missed two or more 
appointments in 18 months. A missed appointment was 
defined as failure to attend within 7 days after a 
scheduled appointment. This outcome was chosen as 
late visits result in exhaustion of drug supplies and 
missed doses. Findings of studies have consistently 
shown that missed appointments are associated with 
worse health outcomes.20 Those who transferred to 
another clinic within a month of enrolment (but not 
those who were lost to follow-up) were excluded from 
the analysis of missed visits because during their short 
follow-up they had fewer than two visits scheduled so 
they were not at risk of the outcome (missing two or 
more appointments).
A secondary, composite, outcome was the proportion 
of all participants who were virally unsuppressed, did 
not start ART, died, or were lost to follow-up, defined as 
the participant making no contact with the clinic for 
6 months and not re-entering care elsewhere 18 months 
after enrolment. This outcome was selected to 
investigate the combined effect of the intervention on 
ART initiation, retention in care, and adherence. 
Participants who transferred to another clinic were 
excluded from analysis. Other secondary outcomes 
were all-cause mortality, number of hospital admissions 
(defined as stay in hospital for ≥24 h), number of 
unscheduled visits to a primary health-care clinic 
(defined as any clinic visit not pre-booked), all measured 
over 18 months; and caregiver or self-reported 
adherence (average adherence <90% over 12 months 
post-ART initiation; proportion who reported any 
missed pills in 3 days recall).
Statistical analysis
The primary analyses were complete-case, modified-
intention-to-treat. For binary outcomes, the odds ratio 
(OR) for the intervention effect was estimated using 
mixed-effects logistic regression, adjusting for clinic as a 
fixed effect and with random effects to account for 
correlation at the level of the community health worker. 
As specified a priori, analyses were adjusted for variables 
showing imbalance between groups at baseline. In 
addition, to produce an unbiased complete case analysis, 
analyses of primary outcomes and the composite 
secondary outcome were adjusted for variables associated 
with either the outcome or missingness. Hospital 
admission and unscheduled appointments were analysed 
as count out comes using mixed-effects. Poisson 
regression, adjusted for unbalanced baseline variables 
and clinic as fixed effects, with community health worker 
as a random effect. Sensitivity analyses were performed; 
first, multiple imputation (20 imputations) using 
variables associated with the outcome and with outcome 
missingness for the first primary outcome and the 
composite secondary outcome; second, assuming either 
0% or 100% of all participants who were in care at 
another clinic at follow-up were virally suppressed.
A sample size of 250 participants per group provides 
80% power to detect a 40% reduction in the proportion of 
children missing two or more routine appointments, 
assuming a proportion of 30% in the control group 
and 30% loss-to-follow-up. Assuming 70% of children 
initiated ART within the first 6 months and with a year of 
follow-up, we expected 175 children per group to be 
eligible for the viral load outcome, giving 81% power to 
detect a 30% reduction in treatment failure/death from 
the expected 50% in the control group. Analyses were 
done with STATA v14.0 software (StatCorp, TX, USA).
The trial is registered with the Pan African Clinical 
Trials Registry, number PACTR201212000442288.
Role of the funding source
The funder had no role in any aspect of study design or 
analysis, data collection, data analysis, data interpretation, 
writing of the report, or the decision to submit for 
All trial participants Participants who started ART 
within 6 months of enrolment
Intervention 
group (N=166)
Control group 
(N=168)
Intervention 
group (N=122)
Control group 
(N=116)
Girls 91 (55%) 87 (52%) 70 (57%) 59 (51%)
Boys 75 (45%) 81 (48%) 52 (43%) 57 (49%)
Age (years) 11 (8–13) 11 (8–13) 11 (9–13) 11 (9–13)
Age group (years)
6–9 55 (33%) 62 (37%) 34 (28%) 32 (28%)
10–12 61 (37%) 52 (31%) 46 (38%) 36 (31%)
13–15 50 (30%) 54 (32%) 42 (34%) 48 (41%)
≥1 change in caregiver 102 (63%) 89 (54%) 79 (65%) 60 (52%)
Type of caregiver
Parent/step-parent 88 (53%) 95 (57%) 64 (53%) 64 (55%)
Aunt/uncle 40 (24%) 32 (19%) 28 (23%) 21 (18%)
Grandparent 27 (16%) 29 (17%) 22 (18%) 22 (19%)
Sibling 9 (5%) 8 (5%) 6 (5%) 6 (5%)
Nephew/niece 1 (1%) 2 (1%) 1 (1%) 1 (1%)
Institution 1 (1%) 2 (1%) 1 (1%) 2 (2%)
Orphanhood status
Both parents alive 60 (36%) 71 (42%) 40 (33%) 46 (40%)
Mother alive, father dead/unknown 37 (22%) 29 (17%) 28 (23%) 25 (22%)
Father alive, mother dead/unknown 36 (22%) 35 (21%) 28 (23%) 21 (18%)
Both parents dead/unknown 33 (20%) 33 (20%) 26 (21%) 24 (21%)
Health status
Wasting (weight for age z-score <–2) 32 (19%) 40 (24%) 29 (24%) 35 (30%)
Stunting (height-for-age z-score <–2) 23 (14%) 30 (18%) 23 (19%) 25 (22%)
CD4 count (cells per µl) 378 
(215–559)
376 
(223–610)
286  
176–463)
292 
(160–413)
CD4 count ≤350 cells per µl 75 (45%) 78 (47%) 75 (62%) 73 (64%)
Data are n (%) or median (IQR).
Table 1: Characteristics of participants at baseline and of the 238 participants who started ART within 
6 months of enrolment
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publication. RAF, HW, TB, and VS had full access to all 
data. RAF had final responsibility for the decision to 
submit for publication.
Results
Between January, 2013, and January, 2015, 470 par ticipants 
tested HIV-positive at study primary health-care clinics 
and were screened for eligibility. Of the 334 eligible 
children, 166 were randomly assigned to the intervention 
group and 168 to the control group (figure 1). The median 
age was 11 years (IQR 8–13 years), and 178 (53%) 
participants were girls (table 1). Because of slight 
imbalances in age and sex by group, these variables 
were adjusted for in outcome analyses. One participant 
withdrew from the trial 240 days after enrolment and 
12 died during follow-up (five in the intervention group; 
seven in the control group). Of the remaining participants, 
36 (22%) in the intervention group and 34 (20%) in 
the control group did not complete 18 months of trial 
follow-up, of whom 28 (17%) and 14 (8%) participants, 
respectively, had a facilitated transfer to another clinic 
with referral letters including a detailed clinical history to 
ensure continuity of care (table 2). There was no 
significant difference in the proportion of participants 
who missed two or more scheduled clinic visits (17% vs 
18%; adjusted OR (aOR) 0·92, 95% CI 0·49–1·74; p=0·79; 
table 3). This proportion varied considerably by clinic, 
ranging from 2–44% (data not shown).
6 months after enrolment, 238 (71%) participants had 
initiated ART, 122 (73%) in the intervention and 
116 (69%) in the control group (table 1). At end of follow-
up, 14% of participants still in care had not initiated 
ART, as they were still not eligible. The estimated rate 
ratio of initiating ART in the intervention compared to 
the control group was 1·24 (95% CI 0·97–1·58; p=0·08; 
figure 2). Among the 238 participants who initiated 
ART within 6 months of randomisation, 172 (72%) were 
followed up to 12 months after initiation and had a viral 
load measurement, while eight died within 12 months. 
The proportion with unsuppressed viral load or death 
was lower in the intervention group than the control 
group (31 [33%] of 94 participants vs 42 [49%] of 86, 
respectively; aOR 0·46, 95% CI 0·23–0·89; p=0·02; 
table 3). Among all participants, the proportion with 
unsuppressed viral load, death, not initiating ART, or 
who were lost to follow-up at 18 months was lower in 
the intervention group than the control group (49 [44%] 
of 112 participants vs 69 [58%] of 119 participants, 
respectively; aOR=0·50, 95% CI 0·28–0·89, p=0·02; 
table 3). Estimates of the inter vention effect were similar 
using multiple imputation and sensitivity analyses for 
the composite outcome also showed similar results 
(appendix). In addition, in a post-hoc analysis, similar 
results were obtained for a composite endpoint of death, 
lost to follow-up, and unsuppressed viral load (38 [38%] 
of 101 in the intervention group vs 50 [50%] of 100 in the 
control group, aOR 0·53, 95% CI 0·28–0·99; p=0·046).
There was no evidence of an intervention effect on 
mortality, number of hospital admissions, or number 
of unscheduled clinic visits (table 3). No participant 
switched to second line treatment.
Intervention group 
(N=166)
Control group 
(N=168)
In care at the study clinic 125 (75%) 126 (75%)
Died 5 (3%) 7 (4%)
Withdrew from trial—but stayed in care at the same clinic 0 1 (1%)
Transferred to another clinic (planned transfer) 28 (17%) 14 (8%)
Transferred to another clinic without official transfer* 2 (1%) 9 (5%)
Moved away without forwarding address* 2 (1%) 5 (3%)
Untraceable* 4 (2%) 6 (4%)
*Ascertained through phone calls and home visits.
Table 2: Retention in care at 18 months
Intervention 
group
Control group Adjusted odds ratio 
(95% CI)
Primary outcomes
Proportion of patients who died or had an 
HIV viral load ≥400 copies per mL 12 months 
after ART initiation* 
31/94 (33%) 42/86 (49%) 0·46 (0·23–0·89); 
p=0·02
Proportion of patients with ≥2 missing or 
late scheduled visits in 18 months†‡
27/155 (17%) 30/165 (18%) 0·92 (0·49–1·74); 
p=0·79
Secondary outcomes
Composite outcome: proportion not 
initiating ART, virally unsuppressed, died or 
lost to follow-up 18 months after enrolment§
49/112 (44%) 69/119 (58%) 0·50 (0·28–0·89); 
p=0·02
All-cause mortality* 5/166 (3%) 7/168 (4%) 0·72 (0·22–2·41); 
p=0·59
Proportion with adherence <90% 12 months 
after ART initiation¶
7/94 (8%) 7/80 (9%) 0·75 (0·24–2·35); 
p=0·62
Proportion who missed all pills for ≥1 day out 
of the 3 previous days¶
3/94 (3%) 5/80 (6%) 0·58 (0·13–2·60); 
p=0·48
Number of hospital admissions†
0 154 (93%) 148 (88%) 0·59|| (0·31–1·12); 
p=0·11
1 9 (5%) 15 (9%) ··
2 3 (2%) 3 (2%) ··
3 0 2 (1%) ··
Number of unscheduled attendances†
0 117 (71%) 121 (72%) 0·83|| (0·60–1·17); 
p=0·29
1 40 (24%) 32 (19%) ··
2 6 (4%) 8 (5%) ··
3 2 (1%) 3 (2%) ··
4–6 1 (1%) 4 (2%) ··
*58 missing viral load: 29=non-attendance in the 40–75 week period; 5=viral load test failed; 24=child refused or logistic 
issues with sampling. †Adjusted for clinic, age, sex, and community health worker (a priori). ‡14 missing outcome: 
9=missing data; 5=transferred out within 30 days of enrolment. §Adjusted for clinic, age, sex, community health worker 
(a priori), baseline CD4 count (associated with outcome), wasting and stunting (associated with missingness). 
103 missing outcome: 1=withdrew from trial; 53=transferred to another clinic for care; 49=logistic issues with blood 
sampling. ¶Measured 41–75 weeks after ART initiation in 174 of 238 participants who started ART within 6 months; 
9=died; 26=did not complete adherence questionnaire; 29=did not attend clinic during this period. If adherence 
measured more than once, closest time-point to a year post-ART initiation used for the outcome. Adjusted for age, sex, 
and community health worker. ||Adjusted incidence rate ratio.
Table 3: Primary and secondary outcomes
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Discussion
This is the first trial of an adherence support intervention 
to show an effect on HIV viral suppression in older 
children and adolescents. Our trial found 54% lower 
odds of virological failure or death among participants 
receiving community-based support by community 
health workers compared with those receiving HIV care 
solely at primary care facilities. Only half the par ticipants 
achieved viral suppression in the control group 
(compared with two-thirds of those in the intervention 
group), despite provision of decentralised care provided 
by trained specialist nurses in both groups. This finding 
underscores the need for actively supporting adherence 
to treatment. Notably, although we noted a substantial 
intervention effect on viral suppression, there was no 
difference in self-reported adherence and participants in 
both groups probably over-estimated adherence.21 This 
has been reported by several studies and highlights the 
importance of using viral load measures to ascertain 
treatment outcomes.22,23
There have been no adherence interventions that have 
improved virological outcomes among populations 
living with HIV in low and middle-income countries 
(LMIC), but trials have been sparse. In a network meta-
analysis of randomised controlled trials aimed at 
improving adherence, cognitive behaviour therapy and 
supporter interventions had modest effects on HIV viral 
suppression compared with standard of care in all study 
settings, but none of the interventions improved viral 
load in studies done in LMICs.24 Support interventions 
including peer or community support have shown a 
modest effect on adherence but not on viral suppression 
in adults in LMICs, despite these interventions being 
widely promoted and recom mended.25,26 Most have been 
in high-income countries with interventions that are 
difficult to implement in resource-limited settings. In 
addition, the studies have been limited by small sample 
sizes, short follow-ups, lack of adequate control groups, 
and reliance on self-reported measures of adherence.5,6
Although there was an effect of the intervention on 
viral load, there was no difference between groups in 
the proportion of participants who missed two or more 
clinic visits. This finding might be explained by the 
close proximity to the clinics and high quality of care 
provided by the research nurses in both groups. Notably, 
the proportion of missed visits varied substantially 
between clinics, suggesting that missing visits was 
affected by local context. For example, visits were more 
frequent than stipulated by national guidelines as 
adequate ART supplies to cover 3 months were not 
always available. Additional visits to collect prescriptions 
(counted as routine appointments) had to be scheduled 
and therefore the frequency of pharmacy visits varied 
by clinic. Reassuringly, the all-cause mortality and 
hospitalisation rates were low, which shows that it is 
feasible to provide effective paediatric HIV care in 
primary care settings.
By 18 months post-enrolment, 75% of participants 
were still engaged with care, with no difference by 
group. This finding is similar to findings from other 
pediatric cohorts in LMICs, which were mostly hospital-
based.27 The intervention had an effect on the composite 
secondary outcome, which takes into account all the 
steps of the HIV care cascade following diagnosis 
namely assessment for ART eligibility, ART initiation, 
and adherence. Notably, the intervention was provided 
to all participants irrespective of whether they were 
eligible for ART. Community health workers were 
tasked to emphasise the importance of staying in care 
and to address participants concerns about their 
children starting ART. Despite trial groups having 
similar baseline CD4 counts, a higher proportion of 
intervention group participants were taking ART after 
3 months of enrolment, and had significantly lower risk 
of the composite outcome (not starting ART, lost to 
follow-up, death, or virological failure) than the control 
group. Among those who left care at the study clinics, 
intervention group participants were significantly more 
likely to inform clinic staff of their intention to transfer 
to another clinic. This ensured a coordinated process 
for continuity of care, which is especially important for 
children who often experience unstable caregiving 
arrangements because of parental illness or 
orphanhood.28 Only 40% of participants had both 
parents alive and over half had had more than one 
change of caregiver.
The trial was done before the “treat all” strategy was 
recommended. However, most participants in our trial 
were eligible for ART at diagnosis and started ART 
shortly after diagnosis. With the treat-all strategy in this 
age group, a small proportion would not have been 
eligible based on national guidelines at the time of the 
study. We cannot extrapolate the effect of the 
intervention on viral load in this sub-group. Treating all 
irrespective of CD4 count does streamline the ART 
initiation procedure and it is possible that such an 
Figure 2: Proportion of participants initiated on ART over time, by trial group
Rate ratio=1·24 (95% CI 0·97−1·58), p=0·08
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approach could reduce the difference in the composite 
outcome (which includes proportion who initiated 
ART). Notably, in a post-hoc analysis, there was still a 
significant difference in the composite outcome when 
ART initiation was excluded. Community support has 
been described as a safety net that improves adherence 
by reducing patients’ social isolation, increasing their 
understanding of the importance of treatment, and 
helping to tackle stigma.29 Our trial was based on the 
hypothesis that HIV outcomes are affected by caregivers’ 
awareness and willingness to invest effort into accessing 
care, and therefore supporting caregivers would 
translate into better outcomes for their children. 
The intervention mainly targeted caregivers, and 
improvement in viral suppression might have been 
mediated by caregivers’ increased capacity to support 
children in taking treatment. Furthermore, community 
health workers were tasked with supporting caregivers 
to disclose to children their HIV status, which is 
associated with improved adherence and retention in 
care.30 A formal process assessment will be reported 
separately. Our intervention incorporated formalised 
management procedures, on going supervision and 
mentorship, monthly debriefs, and clear working 
guidelines. The intervention aligned with formal health 
system procedures, including regular meetings between 
community health workers and clinic staff. These 
components are crucial to the success and sustainability 
of community health worker programmes.31 It is 
important to note that while the intervention had a 
significant effect on viral suppression at 12 months after 
ART initiation and on the composite outcome, a 
substantial proportion in the intervention group still 
had poor outcomes. It is unlikely that one intervention 
will suffice to achieve optimum outcomes among 
children and adolescents; instead a multi-pronged 
approach will be required.
A major strength of this trial is that it was done in a 
routine health-care setting using a cadre of community 
health workers that exist in many African health systems, 
which means that implementing the intervention should 
be feasible in similar settings. However, context specific 
evaluations will be required to understand factors that 
would influence implementation such as cost and other 
local factors. Additionally, rigorous procedures were used 
to ascertain outcomes. Limitations include a smaller 
sample size than planned as HIV prevalence among older 
children attending primary health-care clinics was lower 
than in previous estimates, resulting in lower study power 
than originally planned. Nonetheless, there was strong 
evidence of an intervention effect. Viral load data were 
missing in a proportion of participants. Sensitivity 
analyses including multiple imputation showed similar 
effect estimates. Another limitation was a lack of cost-
effectiveness data.
Health systems in many settings are overstretched as 
increasing numbers of individuals access ART. The 2016 
WHO guidelines recommend treatment of all individuals 
living with HIV irrespective of disease stage, and a 
projected additional 21 million people globally will need 
ART.32 Furthermore, UNAIDS has set ambitious targets to 
identify 90% of HIV-positive persons through testing, to 
have 90% of diagnosed people on ART, and viral 
suppression in 90% of those on ART by 2020.33 Community 
based approaches to support retention in care and 
adherence are being promoted as a means to contribute to 
these targets.32 Our trial is the first to show the effectiveness 
of such an approach and the first adherence intervention 
to improve viral suppression in children and adolescents, 
an age group with disproportionately poor HIV treatment 
outcomes. To scale up community-based interventions, 
careful attention needs to be paid to training and 
mentoring community workers, addressing contextual 
issues, and monitoring for quality assurance.
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